We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+49.88%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.33B
AUM Growth
+$851M
Cap. Flow
+$41.1M
Cap. Flow %
0.77%
Top 10 Hldgs %
79.43%
Holding
93
New
17
Increased
12
Reduced
17
Closed
13

Top Buys

Rank Stock Value
1
MBLY
Mobileye N.V.
MBLY
+$15.6M
2
V icon
Visa
V
+$13.6M
3
JPM icon
JPMorgan Chase
JPM
+$13M
4
CELG
Celgene Corp
CELG
+$11.6M
5
YUM icon
Yum! Brands
YUM
+$10.9M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.2M
2
BAC icon
Bank of America
BAC
+$15.6M
3
LNKD
LinkedIn Corporation
LNKD
+$5.67M
4
KITE
Kite Pharma, Inc.
KITE
+$2.82M
5
NKTR icon
Nektar Therapeutics
NKTR
+$2.74M

Sector Composition

Rank Sector Weight
1 Consumer Staples 40.39%
2 Healthcare 20%
3 Consumer Discretionary 13.89%
4 Financials 1.45%
5 Technology 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BUFF
1
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
$2.15B 40.39%
114,987,547
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.04B
$766M 14.37%
57,517,977
-1
-0% -$12
WW
3
DELISTED
WW International
WW
$671M 12.6%
29,443,300
– –
GS icon
4
CALL
Goldman Sachs
GS
$305B
$135M 2.54%
750,000
+250,000
+50% +$46.5M
BIIB icon
5
CALL
Biogen
BIIB
$30.4B
$107M 2.01%
350,000
-50,000
-13% -$14.4M
WMT icon
6
CALL
Walmart Inc
WMT
$900B
$102M 1.92%
4,995,000
– –
CELG
7
CALL
DELISTED
Celgene Corp
CELG
$95.8M 1.8%
800,000
+150,000
+23% +$17.4M
MET icon
8
CALL
MetLife
MET
$62.7B
$72.3M 1.36%
1,683,000
+280,500
+20% +$12.3M
INCY icon
9
Incyte
INCY
$26B
$61.8M 1.16%
570,000
+80,000
+16% +$8.92M
JPM icon
10
CALL
JPMorgan Chase
JPM
$950B
$56.1M 1.05%
850,000
-450,000
-35% -$29.3M
SPY icon
11
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$51M 0.96%
+250,000
New +$51.3M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$38.5B
$44.7M 0.84%
475,000
+40,000
+9% +$3.71M
BMY icon
13
CALL
Bristol-Myers Squibb
BMY
$130B
$34.4M 0.65%
500,000
– –
GM icon
14
CALL
General Motors
GM
$81.7B
$34M 0.64%
1,000,000
– –
IBB icon
15
CALL
iShares Biotechnology ETF
IBB
$9.55B
$33.8M 0.64%
+300,000
New +$32.6M
MS icon
16
CALL
Morgan Stanley
MS
$333B
$31.8M 0.6%
1,000,000
– –
GILD icon
17
CALL
Gilead Sciences
GILD
$167B
$30.4M 0.57%
300,000
– –
TEVA icon
18
CALL
Teva Pharmaceuticals
TEVA
$36.9B
$29.5M 0.55%
450,000
– –
MA icon
19
Mastercard
MA
$497B
$29.2M 0.55%
300,000
– –
BMRN icon
20
BioMarin Pharmaceuticals
BMRN
$12B
$28.8M 0.54%
275,000
-165,000
-38% -$17.2M
NKTR icon
21
Nektar Therapeutics
NKTR
$2.39B
$27M 0.51%
106,667
-13,333
-11% -$2.74M
MRK icon
22
CALL
Merck
MRK
$326B
$26.4M 0.5%
524,000
– –
QCOM icon
23
CALL
Qualcomm
QCOM
$172B
$25M 0.47%
500,000
– –
BABA icon
24
CALL
Alibaba
BABA
$276B
$24.4M 0.46%
300,000
-200,000
-40% -$15.7M
BABA icon
25
Alibaba
BABA
$276B
$24.4M 0.46%
300,000
– –
1
2 3 4

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2015 Portfolio in Review

As of Q4 2015, Artal Group held 93 positions worth $5.33B, up 19% from $4.48B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Artal Group's Q4 2015 filing shows 17 new, 12 increased, 17 reduced and 13 closed positions. Its largest new stake was Mobileye N.V.: 350,000 shares worth $14.8M. The largest sale was BioMarin Pharmaceuticals, an estimated $17.2M.

By sector, the portfolio is most concentrated in Consumer Staples at 40% of assets, down from 46% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Artal Group's largest Q4 2015 buy was Mobileye N.V.: 350,000 shares worth $14.8M.
  • Artal Group added most to Yum! Brands in Q4 2015, an estimated $10.9M increase.
  • Artal Group's biggest Q4 2015 reduction was BioMarin Pharmaceuticals, cutting an estimated $17.2M.
  • Artal Group fully exited Bank of America in Q4 2015, selling an estimated $15.6M.
  • Artal Group's ten largest holdings make up 79% of its $5.33B portfolio in Q4 2015.
  • Artal Group opened 17 new positions and closed 13 in Q4 2015.
  • Artal Group's portfolio value rose 19% quarter-over-quarter to $5.33B.

Based on Artal Group's 13F filing for Q4 2015, filed 12 Feb 2016.